X0609 4 2026-05-26 0001281895 ROCKET PHARMACEUTICALS, INC. RCKT 0001662170 Militello John false C/O ROCKET PHARMACEUTICALS, INC. 9 CEDARBROOK DRIVE CRANBURY NJ 08512 true See Remarks false Stock Option (Right to Buy) 18.75 2026-05-26 4 D 0 10000 D 2028-03-29 Common Stock 10000 0 D Stock Option (Right to Buy) 20.61 2026-05-26 4 D 0 10000 D 2028-06-25 Common Stock 10000 0 D Stock Option (Right to Buy) 14.56 2026-05-26 4 D 0 20000 D 2029-01-28 Common Stock 20000 0 D Stock Option (Right to Buy) 10.85 2026-05-26 4 D 0 10000 D 2029-09-02 Common Stock 10000 0 D Stock Option (Right to Buy) 22.72 2026-05-26 4 D 0 20000 D 2030-02-06 Common Stock 20000 0 D Stock Option (Right to Buy) 23.89 2026-05-26 4 D 0 2000 D 2030-02-10 Common Stock 2000 0 D Stock Option (Right to Buy) 24.82 2026-05-26 4 D 0 18000 D 2030-08-03 Common Stock 18000 0 D Stock Option (Right to Buy) 62.32 2026-05-26 4 D 0 18000 D 2031-02-04 Common Stock 18000 0 D Stock Option (Right to Buy) 19.05 2026-05-26 4 D 0 27003 D 2032-02-14 Common Stock 27003 0 D Stock Option (Right to Buy) 13.12 2026-05-26 4 D 0 28910 D 2032-04-18 Common Stock 28910 0 D Stock Option (Right to Buy) 20.04 2026-05-26 4 D 0 49798 D 2033-02-14 Common Stock 49798 0 D Stock Option (Right to Buy) 30.01 2026-05-26 4 D 0 24545 D 2034-02-16 Common Stock 24545 0 D Stock Option (Right to Buy) 3 2026-05-26 4 A 0 51509 A 2031-05-26 Common Stock 51509 51509 D Stock Option (Right to Buy) 3 2026-05-26 4 A 0 15002 A 2032-02-14 Common Stock 15002 15002 D Stock Option (Right to Buy) 3 2026-05-26 4 A 0 16061 A 2032-04-18 Common Stock 16061 16061 D Stock Option (Right to Buy) 3 2026-05-26 4 A 0 24899 A 2033-02-14 Common Stock 24899 24899 D Stock Option (Right to Buy) 3 2026-05-26 4 A 0 9091 A 2034-02-16 Common Stock 9091 9091 D On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, 3,336 of which will become fully vested and exercisable on March 29, 2019, with the remaining 6,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, 3,336 of which will become fully vested and exercisable on June 25, 2019, with the remaining 6,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, 6,672 of which will become fully vested and exercisable on January 28, 2020, with the remaining 13,328 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, 3,336 of which will become fully vested and exercisable on September 2, 2020, with the remaining 6,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 6, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. This option represents a right to purchase a total of 2,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 10, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. This option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on August 3, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. The option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 4, 2022, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. This option represents a right to purchase a total of 27,003 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. This option represents a right to purchase a total of 28,910 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. This option represents a right to purchase a total of 49,798 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. This option represents a right to purchase a total of 24,545 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 16, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Represents a right to purchase shares of the Issuer's common stock, which will become fully vested on May 26, 2027, subject to the reporting person's continued employment with the Issuer. This option represents a right to purchase a total of 9,091 shares of the Issuer's common stock, one-half of which will become fully vested and exercisable on May 26, 2027, with the remaining shares becoming fully vested and exercisable on May 26, 2028, in each case, subject to the reporting person's continued employment with the Issuer. Vice President of Finance, Treasurer, Principal Accounting Officer /s/ Martin Wilson, as attorney-in-fact for John Militello 2026-05-28